Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Preliminary Study on the Feasibility and Effects of a Mindfulness Intervention for Emotional Distress (MIED)-Based Group Intervention for Adolescents (Online Format)

5 de noviembre de 2026 actualizado por: Xinghua Liu

Background: Emotional distress (anxiety and depressive symptoms) among adolescents is rising globally. In China, the detection rate of depression risk among secondary school students is 24.6%, and that of anxiety risk is 18.1%; comorbidity, relapse and disability rates are all high, seriously affecting adolescents' academic performance, social relationships and quality of life. Mindfulness-based interventions (MBIs) have shown substantial effects in children and adolescents, with meta-analyses reporting a moderate effect size for internalizing problems (Hedges' g = 0.47). Group-based mindfulness interventions for adolescents are feasible: the group format improves efficiency, reduces costs and provides social support. However, existing research remains limited in cultural adaptation and in the systematicity of intervention protocols. The MIED (Mindfulness Intervention for Emotional Distress) system, developed by Professor Liu Xinghua on the basis of MBSR and the Unified Protocol (UP), centres on the "diamond model" of emotional distress, which identifies four core maintaining mechanisms: engagement in life, tolerance of distress, emotional behaviours, and cognitive flexibility. Adult studies of MIED show significant improvement in emotional distress, yet no dedicated study has applied it to adolescents.

Methods: This is an exploratory feasibility study using a single-group pre-post design. It plans to recruit 26 adolescents aged 12-18 years with emotional distress for an 8-week online MIED group intervention for adolescents (two online groups, 12-13 participants per group, with an expected effective sample of 20-24). Data will be collected at multiple time points: baseline, after the 4th session, after the 8th session, and at 1-month follow-up.

Objectives: The primary objective is to evaluate the feasibility of the MIED-based adolescent mindfulness group intervention (recruitment feasibility, retention feasibility, implementation feasibility, acceptability, and safety). The secondary objective is to preliminarily evaluate the intervention's effects on anxiety, depression, stress and other outcomes, and to estimate effect sizes, thereby providing methodological preparation for a subsequent large-scale randomized controlled trial (RCT).

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Mei Yuan
  • Número de teléfono: +8618513356664
  • Correo electrónico: bettyyuan8@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 18 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 12-18 years, minors (junior and senior high school level; special note: individuals who exceed the age criterion due to dropout or leave of absence but are still in junior or senior high school may be included if they meet all other inclusion criteria).

PHQ-9 total score 10-19 or GAD-7 total score 10-14 (either criterion is sufficient, indicating mild to moderate depressive or anxiety symptoms).

Informed consent from both the participant and their parent/legal guardian

Exclusion Criteria:

  • PHQ-9 total score ≥20 or GAD-7 total score ≥15, or clinical diagnosis of severe anxiety or depressive disorder (if severe depression or anxiety, referral to individual therapy is recommended).

PHQ-9 item 9 score ≥2 and clinical interview confirming active suicidal ideation or plan.

Presence of psychotic symptoms, bipolar disorder, or severe self-harm behaviors (requiring medical treatment).

Currently receiving other systematic psychotherapy. Severe cognitive or developmental disorders that prevent understanding of group content.

Unable to use a smartphone (affecting use of AI-assisted tools)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Adolescent Group(online)

Adolescent Group Curriculum:8-week online group curriculum adapted from the adult MIED course for adolescents' cognitive development, social needs and preferences. 8 weekly sessions, 90-120 min each, via video conferencing; 2-3 groups of 9-13 participants (27-30 recruited, expected effective sample 20-24). Based on the MIED diamond model: engagement in life, tolerance of distress, emotional behaviours, cognitive flexibility. Interactive design and AI-assisted tools boost participation and practice adherence; modules refined per prior evidence.

Parent Group Curriculum:Based on the parent group approach in the Chinese UP-A (Pan et al., 2025). Aims: improve parents' understanding of adolescent emotional distress; teach strategies supporting adolescents' mindfulness practice and emotion regulation; improve parent-child communication; support parents' own MIED practice and stress management. 4 sessions, every 2 weeks, 120 min each, online, parallel with the adolescent group.

Adolescent Group: Basic curriculum structure: 8 sessions, once per week, 90-120 minutes per session, 12-20 participants per group. Parent Group Curriculum:Number of sessions: 4 (or 8, synchronized with the adolescent group), once every 2 weeks (or once per week), 120 minutes per session.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Generalized Anxiety Disorder 7-item scale(GAD-7)
Periodo de tiempo: Screening phase(Pre-enrollment screening,T0), Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Anxiety symptoms: Generalized Anxiety Disorder 7-item scale (GAD-7). Scores range from 0 to 21, with higher scores indicating worse outcome (more severe anxiety symptoms)

Screening phase(Pre-enrollment screening,T0), Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)
Patient Health Questionnaire-9(PHQ-9)
Periodo de tiempo: Screening phase(Pre-enrollment screening,T0), Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Depressive symptoms:Patient Health Questionnaire-9, 9 items, self-report;Scores range from 0 to 27, with higher scores indicating worse outcome.

Screening phase(Pre-enrollment screening,T0), Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)
Perceived Stress Scale(PSS-10)
Periodo de tiempo: Screening phase(Pre-enrollment screening,T0), Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Perceived stress:Perceived Stress Scale, 10 items, self-report;Scores range from 0 to 40, with higher scores indicating worse outcome.

Screening phase(Pre-enrollment screening,T0), Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
10-item Connor-Davidson Resilience Scale(CD-RISC-10)
Periodo de tiempo: Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Resilience :Connor-Davidson Resilience Scale-10, 10 items, self-report;Scores range from 0 to 40, with higher scores indicating better outcome

Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)
Difficulties in Emotion Regulation Scale-Short Form(DERS-16)
Periodo de tiempo: Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Difficulties in emotion regulation:Difficulties in Emotion Regulation Scale-Brief, 16 items, self-report;Scores range from 16 to 80, with higher scores indicating worse outcome

Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)
Overall Anxiety Severity and Impairment Scale (OASIS)
Periodo de tiempo: Baseline (T1), Weeks 1, 2, 3, 4 (T2), 5, 6, 7 (during intervention), Week 8 immediately post-intervention (T3), and 1 month(post-intervention follow-up,T4)

The OASIS is a 5-item self-report measure designed to assess the frequency and severity of anxiety symptoms, as well as the extent of anxiety-related functional impairment and avoidance, over the past week. Each item is rated on a 5-point scale from 0 to 4, with total scores ranging from 0 to 20. Higher scores indicate greater overall anxiety severity and impairment. The OASIS has demonstrated good reliability and validity in both clinical and nonclinical samples (Norman et al., 2006).

Baseline (T1), Weeks 1, 2, 3, 4 (T2), 5, 6, 7 (during intervention), Week 8 immediately post-intervention (T3), and 1 month(post-intervention follow-up,T4)
Overall Depression Severity and Impairment Scale (ODSIS)
Periodo de tiempo: Baseline (T1), Weeks 1, 2, 3, 4 (T2), 5, 6, 7 (during intervention), Week 8 immediately post-intervention (T3), and 1 month(post-intervention follow-up,T4)

The ODSIS is a 5-item self-report measure designed to assess the frequency and severity of depressive symptoms, as well as depression-related functional impairment and avoidance, over the past week. Each item is rated on a 5-point scale from 0 to 4, with total scores ranging from 0 to 20. Higher scores indicate greater overall depression severity and impairment. The ODSIS has demonstrated good reliability and validity in both clinical and nonclinical samples (Bentley et al., 2014).

Baseline (T1), Weeks 1, 2, 3, 4 (T2), 5, 6, 7 (during intervention), Week 8 immediately post-intervention (T3), and 1 month(post-intervention follow-up,T4)
Five Facet Mindfulness Questionnaire-Short Form(FFMQ-SF)
Periodo de tiempo: Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Mindfulness level:Five Facet Mindfulness Questionnaire-Short Form, 20 items, self-report; Scores range from 0 to 5 for average item scores and 24-120 for total scores, with higher scores indicating better outcome

Baseline assessment(1 day before session 1,T1), Week4(After session 4,T2) ,Week8(After session 8,T3), and 1 month(post-intervention follow-up,T4)

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Process indicator - attendance rate
Periodo de tiempo: Week 8 (immediately after session 8,T3)

attendance rate. Scores range from 0% to 100%, with higher scores indicating better outcome.

Week 8 (immediately after session 8,T3)
Process indicator -homework completion rate
Periodo de tiempo: Week 8 (immediately after session 8,T3)

Scores range from 0% to 100%, with higher scores indicating better outcome

Week 8 (immediately after session 8,T3)
Process indicator - dropout rate and reasons
Periodo de tiempo: Week 8 (immediately after session 8,T3)

dropout rate and reasons: Scores range from 0% to 100%, with higher scores indicating worse outcome

Week 8 (immediately after session 8,T3)
Acceptability
Periodo de tiempo: Week 8 (immediately after session 8,T3)

self-developed acceptability and satisfaction scale (adolescent/parent version, 1-5 Likert scale).with higher scores indicating better outcome

Week 8 (immediately after session 8,T3)
Adverse Event Records
Periodo de tiempo: Baseline (T1); Week4 (T2) during the intervention; immediately post-intervention at Week 8(T3); and1 month(post-intervention follow-up,T4)

adverse event records (emotional deterioration, self-harm reports, number of crisis triggers);with more records indicating worse outcome

Baseline (T1); Week4 (T2) during the intervention; immediately post-intervention at Week 8(T3); and1 month(post-intervention follow-up,T4)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Xinghua Liu, Peking University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

6 de noviembre de 2026

Finalización primaria (Estimado)

31 de marzo de 2027

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Publicado por primera vez (Actual)

12 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • E20261018

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir